Neofordex (dexamethasone)
- Region
- 🇪🇺 EU
- Active substance
- dexamethasone
- Company
- Laboratoires CTRS - Boulogne Billancourt
- Status
- Application withdrawn
- Therapeutic area
- Multiple Myeloma
- Application
- EMEA/H/C/002418
- ATC
- H02AB02
- Official record
- www.ema.europa.eu
Indication
Treatment of symptomatic multiple myeloma
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Neofordex Authorised · THERAVIA
- 🇪🇺 Ozurdex Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Dexamethasone Taw Application withdrawn · Taw Pharma (Ireland) Ltd
Follow Neofordex
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.